Activity of compound 7 was comparable to gefitinib.
Molecular docking results indicated favorable binding affinity to the EGFR-TK domain.
Resumen
, comparable with that of gefitinib. Collectively, these findings highlight compound 7 as a potent EGFR-targeting kinase inhibitor with notable anticancer activity.